University of Chicago: Multiple Myeloma trials

The registry lists 15 Multiple Myeloma studies with University of Chicago as lead sponsor. 3 are open to participants now and 4 have results posted.

Phase 1 4Phase 2 7Phase 3 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)Not yet recruitingNCT07871747Phase 1
• Hypofractionation (Radiation) Trial for Multiple MyelomaRecruitingNCT06270888Phase 1
• Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple MyelomaRecruitingNCT05789303Phase 2
• Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple MyelomaCompletedNCT02969837Phase 2Results posted
• Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell TransplantCompletedNCT02389517Phase 2Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01816971Phase 2Results posted
• Combined Haploidentical-Cord Blood Transplantation for Adults and ChildrenCompletedNCT00943800Not applicableResults posted
• Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive CarfilzomibTerminatedNCT04827563
• Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma PatientsActive, not recruitingNCT04108624Not applicable
• Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)Active, not recruitingNCT03729804Phase 3
• Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple MyelomaActive, not recruitingNCT03500445Phase 2
• Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple MyelomaActive, not recruitingNCT02659293Phase 3
• Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02199665Phase 1
• Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01665794Phase 1/2
• Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00004145Phase 2